Fierce Biotech reported today on the continued hype by investors and analysts for the companies that are pursuing hepatitis C therapies and have gotten good clinical (or preclinical) results. Two of the leaders who have not yet been swallowed, Achillion and Idenix, are rumored to be takeover targets as big pharma suitors cast an eye toward a purported $20 billion hepatitis C treatment market.
Achillion's CEO, Michael Kishbauch, is out shopping the company to large, as yet unnamed, players. He says he is looking for a premium that would "put a silly grin on all our faces." He might just get it too. But other Big Pharma CEO's like Sanofi's Viehbacher are saying the premium's are too high and the value is not there. This is echoed by GSK's Moncef Slaoui, R&D chief.
Next thing you know, Sanofi and GSK will be putting in a bid.
Posted by Bruce Lehr Feb 15th 2012.
Comments